Literature DB >> 27101910

Bioresorption and Vessel Wall Integration of a Fully Bioresorbable Polymeric Everolimus-Eluting Scaffold: Optical Coherence Tomography, Intravascular Ultrasound, and Histological Study in a Porcine Model With 4-Year Follow-Up.

Shimpei Nakatani1, Yuki Ishibashi1, Yohei Sotomi2, Laura Perkins3, Jeroen Eggermont4, Maik J Grundeken2, Jouke Dijkstra4, Richard Rapoza3, Renu Virmani5, Patrick W Serruys6, Yoshinobu Onuma7.   

Abstract

OBJECTIVES: The aim of the present study was to investigate the relationship between the integration process and luminal enlargement with the support of light intensity (LI) analysis on optical coherence tomography (OCT), echogenicity analysis on intravascular ultrasound, and histology up to 4 years in a porcine model.
BACKGROUND: In pre-clinical and clinical studies, late luminal enlargement has been demonstrated at long-term follow-up after everolimus-eluting poly-l-lactic acid coronary scaffold implantation. However, the time relationship and the mechanistic association with the integration process are still unclear.
METHODS: Seventy-three nonatherosclerotic swine that received 112 Absorb scaffolds were evaluated in vivo by OCT, intravascular ultrasound, and post-mortem histomorphometry at 3, 6, 12, 18, 24, 30, 36, 42, and 48 months.
RESULTS: The normalized LI, which is the signal densitometry on OCT of a polymeric strut core normalized by the vicinal neointima, was able to differentiate the degree of connective tissue infiltration inside the strut cores. Luminal enlargement was a biphasic process at 6 to 18 months and at 30 to 42 months. The latter phase occurred with vessel wall thinning and coincided with the advance integration process demonstrated by the steep change in normalized LI (0.26 [interquartile range (IQR): 0.20 to 0.32] at 30 months versus 0.68 [IQR: 0.58 to 0.83] at 42 months, p < 0.001).
CONCLUSIONS: In this pre-clinical model, late luminal enlargement relates to strut integration into the arterial wall. Quantitative LI analysis on OCT could be used as a surrogate method for monitoring the integration process of poly-l-lactic acid scaffolds, which could provide insight and understanding on the imaging-related characteristics of the bioresorption process of polylactide scaffolds in human.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biodegradable polymer; bioresorbable scaffold; coronary intervention; intravascular ultrasound; optical coherence tomography; pathology

Mesh:

Substances:

Year:  2016        PMID: 27101910     DOI: 10.1016/j.jcin.2016.01.030

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  4 in total

1.  Final report of the 5-year clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in the treatment of single de novo coronary lesions in a first-in-human study.

Authors:  Yizhe Wu; Jiasheng Yin; Jiahui Chen; Zhifeng Yao; Juying Qian; Li Shen; Lei Ge; Junbo Ge
Journal:  Ann Transl Med       Date:  2020-09

2.  Preclinical comparative assessment of a dedicated pediatric poly-L-lactic-acid-based bioresorbable scaffold with a low-profile bare metal stent.

Authors:  Kamel Shibbani; Luiza De Lima E Silva Bagno; Marie-France Poulin; Thomas Matella; Karim Diab; Clifford Kavinsky; Nagarajan Ramesh; Vinayak Bhat; Ziyad M Hijazi; Damien Kenny
Journal:  Catheter Cardiovasc Interv       Date:  2020-04-15       Impact factor: 2.692

3.  Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial.

Authors:  Diego A Arroyo; Sara Schukraft; Zacharenia Kallinikou; Jean-Christophe Stauffer; Gérard Baeriswyl; Jean-Jacques Goy; Mario Togni; Stéphane Cook; Serban Puricel
Journal:  Open Heart       Date:  2018-01-03

4.  Five-year angiographic, OCT and clinical outcomes of a randomized comparison of everolimus and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.

Authors:  Sara Schukraft; Diego Arroyo; Mario Togni; Jean-Jacques Goy; Peter Wenaweser; Mathieu Stadelmann; Gerard Baeriswyl; Olivier Muller; Jean-Christophe Stauffer; Serban Puricel; Stéphane Cook
Journal:  Catheter Cardiovasc Interv       Date:  2021-06-26       Impact factor: 2.585

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.